Rapid MDx on infections
Enlarge image


Rapid MDx on infections

03.09.2012 - EU-funded researchers will use a €6m grant to develop cost-effective molecular diagnostics (MDx) tools for the rapid diagnosis of infections.

The aim is to come up with a test that would reduce the diagnosis time of respiratory tract infections from days to hours, so that the appropriate treatments can be administered as early as possible, giving patients the best possible chance of a swift recovery. These diagnostic products will be based on a novel "sample-in, result-out" technology platform.
The project, titled RID-RTI ('Rapid Identification of Respiratory Tract Infections'), brings together researchers from small and medium-sized enterprises (SMEs), universities and hospitals. The Molecular Diagnostics Research Group at the National University of Ireland, Galway; French diagnostics firm Genewave;  Finnish biotech company Mobidiag; Assistance Publique Hopitaux de Paris; and University College London are part of the consortium. They receive a €6m boost of funding from the EU's Seventh Framework Programme (FP7).
Respiratory tract infections, such as pneumonia, are amongst the top four major causes of morbidity and mortality worldwide. „Speed and accuracy are key to appropriate therapy and survival of the patient. The ultimate objective is to develop new cost effective, user-friendly products that will be routinely used in hospitals“, stated Thomas Barry from the Molecular Diagnostics Research Group at NUI Galway in Ireland. „This could replace time-consuming and labour-intensive methods so that a diagnosis can be achieved within a couple of hours, rather than days or weeks.“


09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • ZELTIA (E)4.12 EUR22.99%
  • WILEX (D)2.20 EUR10.00%
  • DEINOVE (F)6.85 EUR7.54%


  • IMMUPHARMA (UK)28.50 GBP-12.98%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • THROMBOGENICS (B)4.08 EUR43.7%
  • OREXO (S)65.25 SEK40.9%
  • ZEALAND PHARMA (DK)155.00 DKK26.0%


  • THERAMETRICS (CH)0.04 CHF-33.3%
  • IMMUPHARMA (UK)28.50 GBP-30.1%


  • KARO BIO (S)43.10 SEK5221.0%
  • CHRONTECH PHARMA (S)0.34 SEK325.0%
  • GALAPAGOS (B)38.85 EUR237.5%


  • NEOVACS (F)0.72 EUR-76.7%
  • BIOTEST (D)19.00 EUR-74.8%
  • EVOCUTIS (UK)0.16 GBP-70.9%

No liability assumed, Date: 09.10.2015